Milagros Balbín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Milagros Balbín has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Ana Sánchez-Pitiot
Laboratorio de Oncología Molecular, Laboratorio de Medicina Hospital Universitario Central de Asturias Oviedo Spain
4 shared publications - Xose S. Puente
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain
3 shared publications - Ander Díaz-Navarro
Ontario Institute for Cancer Research, Toronto, ON, Canada; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
2 shared publications - Alberto Cascón
Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain
1 shared publication - Alberto Díaz-Talavera
Hereditary Endocrine Cancer Group, Cancer Genomics Program, Spanish National Cancer Research Centre (CNIO) , Madrid
1 shared publication - Alicia Arenas
Pharmacogenomics and Tumor Biomarkers Group, Institute for Biomedical Research Sols-Morreale (IIBM) CSIC/UAM, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (2) , 101705
Molecular profiling unveils genetic complexity and identifies potential new driver mechanisms in head and neck paragangliomas
- 1 March 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (2) , 101705
Open AccessMolecular profiling unveils genetic complexity and identifies potential new driver mechanisms in head and neck paragangliomas
- Open Access
- 24 June 2024
- Published by Wiley in Clinical Genetics
- Vol. 106 (4) , 525-531
Featuring BRCA1 and BRCA2 germline mutational landscape from Asturias (North Spain)
The singular BRCA1/2 mutational landscape of Asturias is updated 10 years after the first study. We analyzed BRCA1 and BRCA2 pathogenic variants in 1653 index cases. In total, 238 families were identified to carry a pathogenic variant, 163 families in BRCA1 and 75 families in BRCA2. This yielded a prevalence rate of 14.4%. Seven recurrent variants were found accounting for 55% of the cases. Among them, three are widely distributed (BRCA1 c.211A>G, c.470_471del and c.3331_3334del) and four had been reported as novel in Asturias: two in BRCA1 (c.1674del and c.2901_2902dup) and two in BRCA2 (c.2095C>T and c.4040_4035delinsC). A common haplotype was established for all recurrent variants indicating a shared ancestral origin. Three splicing analyses are shown: BRCA1:c.5152+3A>C and BRCA1:c.5333‐3T>G that lead to skipping of exon 18, and 22 respectively, and BRCA1:c.5278‐1G>T giving rise to two transcripts, one lacking exon 21 (p.Ille1760Glyfs*60) and one lacking the first 8 nucleotides of exon 21 (p.Phe1761Asnfs*14), supporting pathogenicity for these variants.
- 24 June 2024
- Published by Wiley in Clinical Genetics
- Vol. 106 (4) , 525-531
Open AccessFeaturing BRCA1 and BRCA2 germline mutational landscape from Asturias (North Spain)
The singular BRCA1/2 mutational landscape of Asturias is updated 10 years after the first study. We analyzed BRCA1 and BRCA2 pathogenic variants in 1653 index cases. In total, 238 families were identified to carry a pathogenic variant, 163 families in BRCA1 and 75 families in BRCA2. This yielded a prevalence rate of 14.4%. Seven recurrent variants were found accounting for 55% of the cases. Among them, three are widely distributed (BRCA1 c.211A>G, c.470_471del and c.3331_3334del) and four had been reported as novel in Asturias: two in BRCA1 (c.1674del and c.2901_2902dup) and two in BRCA2 (c.2095C>T and c.4040_4035delinsC). A common haplotype was established for all recurrent variants indicating a shared ancestral origin. Three splicing analyses are shown: BRCA1:c.5152+3A>C and BRCA1:c.5333‐3T>G that lead to skipping of exon 18, and 22 respectively, and BRCA1:c.5278‐1G>T giving rise to two transcripts, one lacking exon 21 (p.Ille1760Glyfs*60) and one lacking the first 8 nucleotides of exon 21 (p.Phe1761Asnfs*14), supporting pathogenicity for these variants.
- Open Access
- 1 January 2023
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 13, e2023434
Fatal sclerosing mesenteritis: a 7-year-old male autopsy case report
Autops Case Rep, vol.13, e2023434, 2023
- 1 January 2023
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Autopsy Case Reports
- Vol. 13, e2023434
Open AccessFatal sclerosing mesenteritis: a 7-year-old male autopsy case report
Autops Case Rep, vol.13, e2023434, 2023
- Open Access
- 14 March 2022
- Published by Springer Nature in npj Genomic Medicine
- Vol. 7 (1) , 1-12
PanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2
Current somatic mutation callers are biased against repetitive regions, preventing the identification of potential driver alterations in these loci. We developed a mutation caller for repetitive regions, and applied it to study repetitive non protein-coding genes in more than 2200 whole-genome cases. We identified a recurrent mutation at position c.28 in the gene encoding the snRNA U2. This mutation is present in B-cell derived tumors, as well as in prostate and pancreatic cancer, suggesting U2 c.28 constitutes a driver candidate associated with worse prognosis. We showed that the GRCh37 reference genome is incomplete, lacking the U2 cluster in chromosome 17, preventing the identification of mutations in this gene. Furthermore, the 5′-flanking region of WDR74, previously described as frequently mutated in cancer, constitutes a functional copy of U2. These data reinforce the relevance of non-coding mutations in cancer, and highlight current challenges of cancer genomic research in characterizing mutations affecting repetitive genes.
- 14 March 2022
- Published by Springer Nature in npj Genomic Medicine
- Vol. 7 (1) , 1-12
Open AccessPanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2
Current somatic mutation callers are biased against repetitive regions, preventing the identification of potential driver alterations in these loci. We developed a mutation caller for repetitive regions, and applied it to study repetitive non protein-coding genes in more than 2200 whole-genome cases. We identified a recurrent mutation at position c.28 in the gene encoding the snRNA U2. This mutation is present in B-cell derived tumors, as well as in prostate and pancreatic cancer, suggesting U2 c.28 constitutes a driver candidate associated with worse prognosis. We showed that the GRCh37 reference genome is incomplete, lacking the U2 cluster in chromosome 17, preventing the identification of mutations in this gene. Furthermore, the 5′-flanking region of WDR74, previously described as frequently mutated in cancer, constitutes a functional copy of U2. These data reinforce the relevance of non-coding mutations in cancer, and highlight current challenges of cancer genomic research in characterizing mutations affecting repetitive genes.
- 6 October 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (14) , 1894-1896
Transplacental transfer of essential thrombocythemia in monozygotic twins
- 6 October 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (14) , 1894-1896
Transplacental transfer of essential thrombocythemia in monozygotic twins